XenoPort, Inc. (NASDAQ:XNPT)
A biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
zzlangerhans
(99.26)
Submitted: 1/27/2012 11:37:56 PM :
Start Price:
$4.19
XNPT Score:
-0.27
I really need to stop outperforming stocks into drug launches. My last green thumb on Xenoport set me back rather severely in my quest for score leadership. In return for my faith I got 0.6M in quarterly Horizant revenues and yet another trial failure, this time with XP21279 in Parkinson's. Now, for a 46M enterprise value the company has a 20M quarterly burn, an sNDA for Horizant in post-herpetic neuropathy on June 9, and a phase III trial of arbaclofen in MS spasticity. Recently approved drugs for PHN haven't made much impact and I think Horizant is destined for the scrap heap. The arbaclofen phase III trial is still in the enrollment stages and that candidate has already failed in two phase II trial is GERD.
The solution? Abandon the Xenoport ship and switch thumbs. There's no crying in baseball and no loyalty in stocks, if you want to grow your brokerage account rather than watch helplessly as it gets shredded. I'm fortunately still in the win column with Xenoport with respect to real money at least, having done well on an impulsive purchase of calls right before Horizant approval.
Recs
siri22
(< 20)
Submitted: 10/19/2011 3:11:39 PM :
Start Price:
$5.37
XNPT Score:
-30.71
Below pre approval price?
Recs
acts20
(85.36)
Submitted: 10/19/2011 1:27:07 PM :
Start Price:
$5.40
XNPT Score:
-30.05
At low witth aproved drug
Recs
crazyidiot
(85.95)
Submitted: 7/9/2011 1:08:26 PM :
Start Price:
$7.23
XNPT Score:
-44.64
Restless legs leads to problems with your heart. If you can take a pill from Xenoport to cure your restless legs I would take it.
Recs
projectchris
(64.84)
Submitted: 6/1/2011 9:38:27 AM :
Start Price:
$7.77
XNPT Score:
-44.57
just tracking
Recs
Recs
KimLanners
(< 20)
Submitted: 4/7/2011 10:46:52 AM :
Start Price:
$10.15
XNPT Score:
-58.43
biotech comeback us technicals
Recs
AndrewGreenBull
(98.79)
Submitted: 4/5/2011 11:18:05 AM :
Start Price:
$6.58
XNPT Score:
+35.29
probably another CRL
Recs
FSaucy
(99.94)
Submitted: 7/22/2010 3:48:38 PM :
Start Price:
$6.19
XNPT Score:
-53.23
Following SAC Capital on this.
Recs
franktejon
(< 20)
Submitted: 7/7/2010 10:25:48 PM :
Start Price:
$6.56
XNPT Score:
-60.02
strong buy
Recs
portefeuille
(99.81)
Submitted: 7/7/2010 12:12:23 PM :
Start Price:
$6.55
XNPT Score:
-56.08
currently my fourth-largest position (see this post -> http://caps.fool.com/Blogs/biopharmaceuticals-xnpt/416742).
Recs
syazic
(72.86)
Submitted: 2/26/2010 9:37:08 AM :
Start Price:
$8.40
XNPT Score:
-70.12
XNPT oversold by shorties.. Intrinsic value is $10-18.
Recs
LegitCompute
(< 20)
Submitted: 2/24/2010 4:03:29 AM :
Start Price:
$8.09
XNPT Score:
-68.72
This stock is likely to sky rocket from its current price of $8.16 within the next few weeks possibly a couple months. The reason behind this is because they just had a better than expected earnings report, and they have the funds to fund their future research. They also just need to revise their new restless leg drug to be able to get it approved by the FDA. This is definitely a bargain stock at the moment, and soon to be a very profitable stock.
Recs
TraderAsh123
(< 20)
Submitted: 2/23/2010 11:19:27 PM :
Start Price:
$8.22
XNPT Score:
-69.68
fill the gap
Recs
Recs
hansjang
(< 20)
Submitted: 2/19/2010 7:48:26 AM :
Start Price:
$6.82
XNPT Score:
-58.41
It should be wait what FDA say for this REJECT.
And, we can do something for this company.
I am waiting for a while.
I believe what XNPT did well.
Recs
BuffetsMentor
(23.54)
Submitted: 2/18/2010 1:47:33 PM :
Start Price:
$6.66
XNPT Score:
-57.00
bizzounce
Recs
riegonla
(38.12)
Submitted: 2/9/2010 9:53:06 PM :
Start Price:
$18.85
XNPT Score:
-102.70
25US$ Feb 2011
Recs
tenmiles
(99.96)
Submitted: 1/28/2010 10:26:36 AM :
Start Price:
$18.92
XNPT Score:
-100.42
Getting restless for a long - playing an anticipated FDA pop in February. Long at $18.82
Recs
Alex1963
(29.94)
Submitted: 9/17/2009 1:18:45 PM :
Start Price:
$24.50
XNPT Score:
-108.88
from article in Morn* 9/17/09
announced positive results Thursday from a Phase IIb clinical trial for XP13512 for neuropathic pain associated with post-herpetic neuralgia. The drug candidate was successful in demonstrating statistically significant results over placebo at all dosing levels, and we plan to slightly raise our fair value estimate in the wake of this news. The 14-week, double-blind trial evaluated the safety and efficacy of XP13512 and had a total enrollment of 375 subjects with PHN who experienced pain following the healing of the herpes zoster (shingles) skin rash for at least three months. XP13512 was statistically significan t on the primary endpoint of the trial, which was improvement from baseline in the 24-hour average pain intensity score. We think this is great news for XenoPort, which experienced a setback with XP13512 in April, when the drug failed a Phase II study for pain associated with diabetes. XenoPort has partnered with GlaxoSmithKline GSK on the drug, which is still on track for final approval from the Food and Drug Administration for restless leg syndrome, having met all primary goals in its Phase III trials.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 28 : 1 2 Next »